CN115996710B - 用于治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物 - Google Patents

用于治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物 Download PDF

Info

Publication number
CN115996710B
CN115996710B CN202180029865.9A CN202180029865A CN115996710B CN 115996710 B CN115996710 B CN 115996710B CN 202180029865 A CN202180029865 A CN 202180029865A CN 115996710 B CN115996710 B CN 115996710B
Authority
CN
China
Prior art keywords
sepsis
triiodothyronine
administration
hypoxia
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180029865.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN115996710A (zh
Inventor
C·潘托斯
I·穆鲁齐斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uni Pharma Kleon Tsetis Pharmaceutical Laboratories SA
Original Assignee
Uni Pharma Kleon Tsetis Pharmaceutical Laboratories SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20200100200A external-priority patent/GR1010068B/el
Priority claimed from GR20200100695A external-priority patent/GR1010182B/el
Priority claimed from GR20210100216A external-priority patent/GR1010261B/el
Application filed by Uni Pharma Kleon Tsetis Pharmaceutical Laboratories SA filed Critical Uni Pharma Kleon Tsetis Pharmaceutical Laboratories SA
Publication of CN115996710A publication Critical patent/CN115996710A/zh
Application granted granted Critical
Publication of CN115996710B publication Critical patent/CN115996710B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202180029865.9A 2020-04-21 2021-04-15 用于治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物 Active CN115996710B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GR20200100200 2020-04-21
GR20200100200A GR1010068B (el) 2020-04-21 2020-04-21 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
GR20200100695 2020-11-23
GR20200100695A GR1010182B (el) 2020-11-23 2020-11-23 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR20210100216 2021-03-29
GR20210100216A GR1010261B (el) 2021-03-29 2021-03-29 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
PCT/GR2021/000019 WO2021214497A1 (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Publications (2)

Publication Number Publication Date
CN115996710A CN115996710A (zh) 2023-04-21
CN115996710B true CN115996710B (zh) 2024-06-28

Family

ID=76197481

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180029865.9A Active CN115996710B (zh) 2020-04-21 2021-04-15 用于治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物

Country Status (13)

Country Link
US (1) US12673036B2 (cg-RX-API-DMAC7.html)
EP (1) EP4138810A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023538984A (cg-RX-API-DMAC7.html)
KR (1) KR102991384B1 (cg-RX-API-DMAC7.html)
CN (1) CN115996710B (cg-RX-API-DMAC7.html)
AU (1) AU2021258544A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021250A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176106A1 (cg-RX-API-DMAC7.html)
GE (2) GEP20247706B (cg-RX-API-DMAC7.html)
IL (1) IL297398B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022013228A (cg-RX-API-DMAC7.html)
WO (1) WO2021214497A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202212502B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20247706B (en) 2020-04-21 2024-12-10 Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
WO1995024919A1 (en) * 1994-03-15 1995-09-21 K.U. Leuven Research & Development New use of growth hormone
US20050059574A1 (en) 2000-12-21 2005-03-17 Irwin Klein Compositions of stable T3 and methodes of use thereof
JP2004525874A (ja) 2000-12-21 2004-08-26 リサスサイテック, インコーポレイテッド 安定したt3の組成物およびその使用方法
US8404281B2 (en) 2009-06-08 2013-03-26 Avant Garde Therapeutics & Technologies Llc Formulations
CN103705497B (zh) 2013-12-11 2015-04-01 武汉威立得生物医药有限公司 碘塞罗宁在制备治疗或预防流感病毒感染的药物中的应用
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
EP3908272B1 (en) 2019-01-09 2023-03-22 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-triiodothyronine (t3) for use in limiting microvascular obstruction
GEP20247706B (en) 2020-04-21 2024-12-10 Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis
GR1010182B (el) 2020-11-23 2022-03-01 Uni Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR1010068B (el) 2020-04-21 2021-09-01 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE" Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Acute left ventricular dysfunction complicating pregnancy on ECMO:Tri-iodothyronine to the rescue with real time transesophageal Echocardiography";Gautam K. Visveswaran ,et al.;《JOURNAL OF CARDIOLOGY CASES》;第13卷(第1期);33-36 *
"Triiodothyronine (T3) Administration in Patients with Sepsis Induced Euthyroid Sick Syndrome:Hemodynamic and Metabolic Effects";Dennis C. Gore,et al.;《SEPSIS》;第2卷(第2期);163-169 *
"Triiodothyronine for the Treatment of Critically III Patients With COVID-19 Infection";ClinicalTrials.gov,Anonymous;https://clinicaltrials.gov/ct2/show/record/NCT04348513;1-10 *

Also Published As

Publication number Publication date
KR102991384B1 (ko) 2026-07-14
BR112022021250A2 (pt) 2022-12-06
ZA202212502B (en) 2024-05-30
IL297398B2 (en) 2026-05-01
IL297398B1 (en) 2026-01-01
IL297398A (en) 2022-12-01
KR20230022839A (ko) 2023-02-16
US12673036B2 (en) 2026-07-07
GEP20247706B (en) 2024-12-10
US20230157982A1 (en) 2023-05-25
AU2021258544A1 (en) 2022-10-27
MX2022013228A (es) 2022-11-14
WO2021214497A1 (en) 2021-10-28
EP4138810A1 (en) 2023-03-01
CA3176106A1 (en) 2021-10-28
JP2023538984A (ja) 2023-09-13
GEAP202416094A (en) 2024-07-10
CN115996710A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
Joannidis et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: expert opinion of the working group for nephrology, ESICM
Kancir et al. The effect of 6% hydroxyethyl starch 130/0.4 on renal function, arterial blood pressure, and vasoactive hormones during radical prostatectomy: a randomized controlled trial
KR20160102301A (ko) 산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도
KR20140053881A (ko) 모세관 누출의 예방 및 치료를 위한 수술 동안 투여되는 프로스타시클린 및 그 유사체
Garrido et al. Small volume of hypertonic saline as the initial fluid replacement in experimental hypodynamic sepsis
KR102776152B1 (ko) 미세혈관 폐쇄를 제한하는 데에 사용하기 위한 l-트리요오도티로닌(t3) (l-triiodothyronine (t3) for use in limiting microvascular obstruction)
JP2025041648A (ja) 心血管有害事象のリスクのある対象における鉄欠乏症の処置
JP6144775B2 (ja) 腎臓病の治療に使用されるアーテミシニンおよびその誘導体
Monogiou Belik et al. The Flt3-inhibitor quizartinib augments apoptosis and promotes maladaptive remodeling after myocardial infarction in mice
Wang et al. Beneficial effects of recombinant human activated protein C in a ewe model of septic shock
US20230157982A1 (en) Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis
GR1010182B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
AU2020206021B2 (en) Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation
GR1010261B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
HK40088108A (en) Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis
HK40088108B (en) Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis
Wollborn et al. Phosphodiesterase-4 inhibition with rolipram attenuates hepatocellular injury in hyperinflammation in vivo and in vitro without influencing inflammation and HO-1 expression
EA048898B1 (ru) Фармацевтическая композиция, содержащая l-трийодтиронин (т3), для применения при лечении тканевой гипоксии и сепсиса
WO2007129618A1 (ja) 好中球の活性化および遊走因子の抑制剤およびその利用
Nugent et al. Low-volume resuscitation with VS-101, a next-generation PEGylated HBOC, improves survival after severe hemorrhagic shock in rats
Perin et al. Low hematocrit impairs gastric mucosal CO2 removal during experimental severe normovolemic hemodilution
Mohamed et al. Propofol versus insulin cardioplegia in valvular heart surgeries assessed by myocardial histopathology and troponin I
EA046425B1 (ru) Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
CN118845745A (zh) 辛酸钠在制备治疗脓毒症药物中的应用
Jones et al. Extracellular fluid volume and EPO dose in haemodialysis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088108

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant